WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001080711) METHOD OF EVALUATING A RISK OF A SUBJECT OF DEVELOPING VASCULAR COMPLICATIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/080711    International Application No.:    PCT/IL2001/000368
Publication Date: 01.11.2001 International Filing Date: 19.04.2001
Chapter 2 Demand Filed:    15.10.2001    
IPC:
C12Q 1/68 (2006.01), G01N 33/68 (2006.01), G01N 33/72 (2006.01), G01N 33/80 (2006.01)
Applicants: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES [IL/IL]; P.O. Box 9697 Haefron Street 31096 Haifa (IL) (For All Designated States Except US).
LEVY, Andrew, P. [IL/IL]; (IL) (For US Only)
Inventors: LEVY, Andrew, P.; (IL)
Agent: G. E. EHRLICH (1995) LTD.; Bezalel Street 28 52521 Ramat Gan (IL).
EHRLICH, Gal; c/o Anthony Castorina 2001 Jefferson Davis Highway Suite 207 Arlington, VA 22202 (US)
Priority Data:
09/556,469 20.04.2000 US
60/237,696 05.10.2000 US
09/688,121 16.10.2000 US
Title (EN) METHOD OF EVALUATING A RISK OF A SUBJECT OF DEVELOPING VASCULAR COMPLICATIONS
(FR) METHODE PERMETTANT D'EVALUER UN RISQUE DE DEVELOPPEMENT DE COMPLICATIONS VASCULAIRES CHEZ UN SUJET
Abstract: front page image
(EN)A method of evaluating a risk of a subject to develop vascular complications is disclosed. The method is effected by determining a haptoglobin phenotype of the subject and thereby evaluating the risk of the subject to develop vascular complications. The risk is decreased in patients with haptoglobin 1-1 phenotype as compared to patients with haptoglobin 1-2 or haptoglobin 2-2 phenotypes.
(FR)L'invention concerne une méthode permettant d'évaluer un risque de développement de complications vasculaires chez un sujet. Cette méthode consiste à déterminer le phénotype d'une haptoglobine chez un sujet, et donc à évaluer le risque de développement de complications vasculaires chez ce sujet. Ce risque est réduit chez des patients ayant le phénotype de l'haptoglobine 1-1 par rapport à des patients ayant les phénotypes de l'haptoglobine 1-2 ou de l'haptoglobine 2-2.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)